Kuros BiosciencesCSBTF 71 5-Year Yield-on-Cost % is 0.00 as of Jul. 02, 2026. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.99 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 328 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 304877.74% on this metric.
Kuros Biosciences's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Kuros Biosciences's 5-Year Yield-on-Cost % or its related term are showing as below:
CSBTF's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.425 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Kuros Biosciences (OTCPK:CSBTF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Kuros Biosciences 5-Year Yield-on-Cost % Related Terms
CSBTF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Kuros Biosciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's 5-Year Yield-on-Cost % falls into.
Kuros Biosciences 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Kuros Biosciences (CSBTF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #999999 out of 328 companies in the Medical Devices & Instruments industry.
Is Kuros Biosciences' 5-Year Yield-on-Cost % too high?
Kuros Biosciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Kuros Biosciences ranks #999999 out of 328 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #999999 out of 328 companies for 5-Year Yield-on-Cost %. This places Kuros Biosciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.99, compared to a current price of $22.72 — trading 58.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.7% below its estimated GF Value™ of $54.99.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $54.99 vs. price of $22.72 (58.7% below fair value)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 